Literature DB >> 7660252

Curative treatment for pancreatic neoplasms. Standard resection.

H A Pitt1.   

Abstract

In the mid-1990s pancreatoduodenectomy can be performed at regional referral centers with an operative mortality of 1% to 2%. In addition, a number of centers around the world are now reporting 5-year survivals between 20% and 30% for patients with resected pancreatic cancer. In recent years a debate has continued as to the proper extent of resection for these patients, in part because numerous resective and reconstructive options are available. In broad terms, operations can be categorized as "standard" or "radical." In general, standard operations tend to have lower postoperative morbidity and mortality. Multiple factors influence postoperative survival, including intraoperative blood loss, perioperative transfusions, type of operation, hospital mortality, tumor biology, and adjuvant therapy. Among these parameters, tumor biology is the most important by multivariate analysis. Recent data suggest that the quality of survival is better with standard operations and best with the pylorus-preserving pancreatoduodenectomy. Nevertheless, debate will continue about the proper extent of resection until a well-controlled randomized trial has addressed this issue.

Entities:  

Mesh:

Year:  1995        PMID: 7660252     DOI: 10.1016/s0039-6109(16)46734-4

Source DB:  PubMed          Journal:  Surg Clin North Am        ISSN: 0039-6109            Impact factor:   2.741


  9 in total

Review 1.  Recent advances in the surgical treatment of pancreatic cancer.

Authors:  A Shankar; R C Russell
Journal:  World J Gastroenterol       Date:  2001-10       Impact factor: 5.742

2.  Guidelines for the management of patients with pancreatic cancer periampullary and ampullary carcinomas.

Authors: 
Journal:  Gut       Date:  2005-06       Impact factor: 23.059

Review 3.  Advances in biomarker research for pancreatic cancer.

Authors:  Kruttika Bhat; Fengfei Wang; Qingyong Ma; Qinyu Li; Sanku Mallik; Tze-Chen Hsieh; Erxi Wu
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

4.  Curative resection of orthotopically implanted pancreatic cancer in Syrian golden hamsters.

Authors:  C Y Morioka; S Saito; K Kita; A Watanabe
Journal:  Int J Pancreatol       Date:  2000-12

5.  Knockdown of microRNA-21 inhibits proliferation and increases cell death by targeting programmed cell death 4 (PDCD4) in pancreatic ductal adenocarcinoma.

Authors:  Imran Bhatti; Andrew Lee; Victoria James; Richard I Hall; Jonathan N Lund; Cristina Tufarelli; Dileep N Lobo; Michael Larvin
Journal:  J Gastrointest Surg       Date:  2010-11-19       Impact factor: 3.452

6.  Feeding patients following pancreaticoduodenectomy: a UK national survey.

Authors:  Mary Phillips; Jeffrey T Lordan; Neville Menezes; Nariman D Karanjia
Journal:  Ann R Coll Surg Engl       Date:  2009-04-30       Impact factor: 1.891

7.  A Circulating Exosome RNA Signature Is a Potential Diagnostic Marker for Pancreatic Cancer, a Systematic Study.

Authors:  Yixing Wu; Hongmei Zeng; Qing Yu; Huatian Huang; Beatrice Fervers; Zhe-Sheng Chen; Lingeng Lu
Journal:  Cancers (Basel)       Date:  2021-05-24       Impact factor: 6.639

8.  Epigenetic regulation and role of metastasis suppressor genes in pancreatic ductal adenocarcinoma.

Authors:  Wolf Arif Mardin; Joerg Haier; Soeren Torge Mees
Journal:  BMC Cancer       Date:  2013-05-29       Impact factor: 4.430

9.  PANasta Trial; Cattell Warren versus Blumgart techniques of panreatico-jejunostomy following pancreato-duodenectomy: Study protocol for a randomized controlled trial.

Authors:  Christopher M Halloran; Kellie Platt; Abbie Gerard; Fotis Polydoros; Derek A O'Reilly; Dhanwant Gomez; Andrew Smith; John P Neoptolemos; Zahir Soonwalla; Mark Taylor; Jane M Blazeby; Paula Ghaneh
Journal:  Trials       Date:  2016-01-15       Impact factor: 2.279

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.